Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.26
+0.21 (2.61%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Zevra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 23.69 | 27.46 | 10.16 | 28.65 | 13.29 | 12.84 | Upgrade
|
| Revenue Growth (YoY) | 43.21% | 170.26% | -64.53% | 115.61% | 3.50% | - | Upgrade
|
| Cost of Revenue | 5.89 | 2.95 | 0.22 | 2.06 | 1.31 | 2.95 | Upgrade
|
| Gross Profit | 17.8 | 24.52 | 9.94 | 26.59 | 11.98 | 9.89 | Upgrade
|
| Selling, General & Admin | 43.79 | 35.09 | 15.61 | 9.23 | 8.44 | 11.42 | Upgrade
|
| Research & Development | 45.74 | 39.03 | 19.23 | 9.64 | 8.32 | 18.82 | Upgrade
|
| Operating Expenses | 92.6 | 74.12 | 34.84 | 18.86 | 16.76 | 30.23 | Upgrade
|
| Operating Income | -74.8 | -49.6 | -24.9 | 7.73 | -4.78 | -20.34 | Upgrade
|
| Interest Expense | -3.97 | -1.5 | -0.34 | -0.38 | -7.09 | -6.51 | Upgrade
|
| Interest & Investment Income | 3.15 | 4.54 | 1.51 | 0.26 | 0.09 | 0.31 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.73 | -0.1 | 15.16 | -0.03 | -0.18 | 2 | Upgrade
|
| EBT Excluding Unusual Items | -66.89 | -46.66 | -8.57 | 7.59 | -11.97 | -24.54 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.83 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.26 | 0.61 | -0.58 | -0.01 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -16.1 | - | - | Upgrade
|
| Pretax Income | -66.63 | -46.05 | -26.81 | -8.52 | -12.79 | -24.54 | Upgrade
|
| Income Tax Expense | 0.18 | - | -0.03 | 0.03 | -0.03 | -0.02 | Upgrade
|
| Net Income | -66.81 | -46.05 | -26.77 | -8.56 | -12.76 | -24.52 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 54.34 | - | - | Upgrade
|
| Net Income to Common | -66.81 | -46.05 | -26.77 | -62.9 | -12.76 | -24.52 | Upgrade
|
| Shares Outstanding (Basic) | 39 | 35 | 34 | 30 | 4 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 35 | 34 | 30 | 4 | 2 | Upgrade
|
| Shares Change (YoY) | 14.39% | 2.79% | 15.87% | 647.71% | 114.79% | 65.39% | Upgrade
|
| EPS (Basic) | -1.70 | -1.30 | -0.78 | -2.11 | -3.21 | -13.23 | Upgrade
|
| EPS (Diluted) | -1.70 | -1.30 | -0.78 | -2.11 | -3.21 | -13.23 | Upgrade
|
| Free Cash Flow | -56.3 | -33.83 | -18.81 | 10.34 | -1.97 | -23.76 | Upgrade
|
| Free Cash Flow Per Share | -1.43 | -0.95 | -0.55 | 0.35 | -0.50 | -12.82 | Upgrade
|
| Gross Margin | 75.13% | 89.28% | 97.82% | 92.81% | 90.18% | 77.06% | Upgrade
|
| Operating Margin | -315.77% | -180.63% | -245.07% | 26.98% | -35.98% | -158.40% | Upgrade
|
| Profit Margin | -282.01% | -167.69% | -263.48% | -219.54% | -96.03% | -191.00% | Upgrade
|
| Free Cash Flow Margin | -237.68% | -123.20% | -185.12% | 36.08% | -14.84% | -185.08% | Upgrade
|
| EBITDA | -70.83 | -48.6 | -23.96 | 7.99 | -4.51 | -20.03 | Upgrade
|
| EBITDA Margin | -299.00% | -176.97% | -235.78% | 27.87% | -33.93% | -156.03% | Upgrade
|
| D&A For EBITDA | 3.97 | 1.01 | 0.94 | 0.26 | 0.27 | 0.3 | Upgrade
|
| EBIT | -74.8 | -49.6 | -24.9 | 7.73 | -4.78 | -20.34 | Upgrade
|
| EBIT Margin | - | -180.63% | -245.07% | 26.98% | -35.98% | -158.40% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.